Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3β inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance

Molecular and Cellular Endocrinology

Volumn 409, Issue , 2015, Pages 1-10

  Kim, Kyoung Min ^a   Lee, Kuy Sook ^a   Lee, Gha Young ^a   Jin, Hyunjin ^a   Durrance, Eunice Sung ^a   Park, Ho Seon ^b   Choi, Sung Hee ^a   Park, Kyong Soo ^b,c   Kim, Young Bum ^c,d   Jang, Hak Chul ^a   Lim, Soo ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diabetes; Diet induced obese mice; GLUT; Glycogen synthase kinase 3; Obesity; OLETF rat

Indexed keywords

2 (4 FLUOROPHENYL) 3H IMIDAZO[4,5 B]PYRIDINE 7 CARBOXYLIC ACID(4 METHYLPYRIDIN 3 YL)AMIDE; ADIPONECTIN; ANTIDIABETIC AGENT; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; AMINOPYRIDINE DERIVATIVE; CARBOXYLIC ACID; GLYCOGEN SYNTHASE KINASE 3; IMIDAZOLE DERIVATIVE; KICG1338; LEPTIN RECEPTOR; LEPTIN RECEPTOR, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GRP78 GENE; HISTOPATHOLOGY; IL 1BETA GENE; INSULIN RESISTANCE; MALE; MCP 1 GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS INJURY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TNF ALPHA GENE; TREATMENT DURATION; TREATMENT OUTCOME; XBP 1 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLUCOSE TOLERANCE TEST; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

AMINOPYRIDINES; ANIMALS; CARBOXYLIC ACIDS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOGEN SYNTHASE KINASE 3; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN RESISTANCE; MICE; MICE, OBESE; RATS; RATS, INBRED OLETF; RECEPTORS, LEPTIN;

EID: 84926486779     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.03.011     Document Type: Article

References (49)

1. Allagnat F., Christulia F., Ortis F., Pirot P., Lortz S., Lenzen S., et al. Sustained production of spliced X-box binding protein 1 (XBP1) induces pancreatic beta cell dysfunction and apoptosis. Diabetologia 2010, 53(6):1120-1130.
2. Asano T., Katagiri H., Tsukuda K., Lin J.L., Ishihara H., Yazaki Y., et al. Upregulation of GLUT2 mRNA by glucose, mannose, and fructose in isolated rat hepatocytes. Diabetes 1992, 41(1):22-25.
3. Azevedo M.F., Camsari C., Sa C.M., Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Ursolic acid and luteolin-7-glucoside improve lipid profiles and increase liver glycogen content through glycogen synthase kinase-3. Phytother. Res 2010, 24(Suppl. 2):S220-S224.
4. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem 2003, 278(46):45937-45945.
5. Burcelin R., Dolci W., Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes 2000, 49(10):1643-1648.
6. Cao J., Feng X., Yao L., Ning B., Yang Z.X., Fang D.L., et al. Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3beta activation in human liver cells. Dig. Dis. Sci 2014, 59(2):346-357.
7. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol 2000, 7(10):793-803.
8. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol 2001, 2(10):769-776.
9. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378(6559):785-789.
10. Eldar-Finkelman H., Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. U.S.A. 1997, 94(18):9660-9664.
11. Eldar-Finkelman H., Schreyer S.A., Shinohara M.M., LeBoeuf R.C., Krebs E.G. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice. Diabetes 1999, 48(8):1662-1666.
12. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem 1980, 107(2):519-527.
13. Flamment M., Hajduch E., Ferré P., Foufelle F. New insights into ER stress-induced insulin resistance. Trends Endocrinol. Metab 2012, 23(8):381-390.
14. Foretz M., Ancellin N., Andreelli F., Saintillan Y., Grondin P., Kahn A., et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005, 54(5):1331-1339.
15. Gibbs E.M., Stock J.L., McCoid S.C., Stukenbrok H.A., Pessin J.E., Stevenson R.W., et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J. Clin. Invest 1995, 95(4):1512-1518.
16. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol 2001, 65(4):391-426.
17. Hagberg C.E., Mehlem A., Falkevall A., Muhl L., Fam B.C., Ortsater H., et al. Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature 2012, 490(7420):426-430.
18. Hanley A.J., Williams K., Festa A., Wagenknecht L.E., D'Agostino R.B., Haffner S.M. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54(11):3140-3147.
19. Hashimoto E., Taniai M., Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J. Gastroenterol. Hepatol 2013, 28(Suppl. 4):64-70.
20. Henriksen E. Dysregulation of glycogen synthase kinase-3 in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. Curr. Diabetes Rev 2010, 6(5):285-293.
21. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406(6791):86-90.
22. Ibrahim S.H., Akazawa Y., Cazanave S.C., Bronk S.F., Elmi N.A., Werneburg N.W., et al. Glycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis. J. Hepatol 2011, 54(4):765-772.
23. Im S.S., Kang S.Y., Kim S.Y., Kim H.I., Kim J.W., Kim K.S., et al. Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes. Diabetes 2005, 54(6):1684-1691.
24. Irimia J.M., Meyer C.M., Peper C.L., Zhai L., Bock C.B., Previs S.F., et al. Impaired glucose tolerance and predisposition to the fasted state in liver glycogen synthase knock-out mice. J. Biol. Chem 2010, 285(17):12851-12861.
25. Kahn B.B., Rossetti L., Lodish H.F., Charron M.J. Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats. J. Clin. Invest 1991, 87(6):2197-2206.
26. Kaidanovich O., Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin. Ther. Targets 2002, 6(5):555-561.
27. Kaidanovich-Beilin O., Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther 2006, 316(1):17-24.
28. Kim Y.M., Song I., Seo Y.H., Yoon G. Glycogen synthase kinase 3 inactivation induces cell senescence through sterol regulatory element binding protein 1-mediated lipogenesis in chang cells. Endocrinol. Metab. (Seoul) 2013, 28(4):297-308.
29. Laybutt D.R., Preston A.M., Akerfeldt M.C., Kench J.G., Busch A.K., Biankin A.V., et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007, 50(4):752-763.
30. Lee S.C., Kim H.T., Park C.H., Lee D.Y., Chang H.J., Park S., et al. Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3beta inhibitors. Bioorg. Med. Chem. Lett 2012, 22(13):4221-4224.
31. Lee S.C., Shin D., Cho J.M., Ro S., Suh Y.G. Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3beta inhibitor. Bioorg. Med. Chem. Lett 2012, 22(5):1891-1894.
32. Leng S., Zhang W., Zheng Y., Liberman Z., Rhodes C.J., Eldar-Finkelman H., et al. Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. J. Endocrinol 2010, 206(2):171-181.
33. Liberman Z., Eldar-Finkelman H. Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. J. Biol. Chem 2005, 280(6):4422-4428.
34. Lim S. Ectopic fat assessment focusing on cardiometabolic and renal risk. Endocrinol. Metab. (Seoul) 2014, 29(1):1-4.
35. Lim S., Moon M.K., Shin H., Kim T.H., Cho B.J., Kim M., et al. Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats. Cardiovasc. Res 2011, 90(2):383-393.
36. Mackenzie R.W., Elliott B.T. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes 2014, 7:55-64.
37. Martinez A., Castro A., Dorronsoro I., Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev 2002, 22(4):373-384.
38. Nikoulina S.E., Ciaraldi T.P., Mudaliar S., Mohideen P., Carter L., Henry R.R. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000, 49(2):263-271.
39. Osawa Y., Seki E., Kodama Y., Suetsugu A., Miura K., Adachi M., et al. Acid sphingomyelinase regulates glucose and lipid metabolism in hepatocytes through AKT activation and AMP-activated protein kinase suppression. FASEB J. 2011, 25(4):1133-1144.
40. Pearce N.J., Arch J.R., Clapham J.C., Coghlan M.P., Corcoran S.L., Lister C.A., et al. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter. Metabolism 2004, 53(10):1322-1330.
41. Postic C., Burcelin R., Rencurel F., Pegorier J.P., Loizeau M., Girard J., et al. Evidence for a transient inhibitory effect of insulin on GLUT2 expression in the liver: studies in vivo and in vitro. Biochem. J. 1993, 293(Pt 1):119-124.
42. Rao R., Hao C.M., Redha R., Wasserman D.H., McGuinness O.P., Breyer M.D. Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57BL/6J mice. Diabetologia 2007, 50(2):452-460.
43. Ring D.B., Johnson K.W., Henriksen E.J., Nuss J.M., Goff D., Kinnick T.R., et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52(3):588-595.
44. Ruderman N.B., Carling D., Prentki M., Cacicedo J.M. AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest 2013, 123(7):2764-2772.
45. Schwabe R.F., Brenner D.A. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol 2002, 283(1):G204-G211.
46. Seto S., Yumoto K., Okada K., Asahina Y., Iwane A., Iwago M., et al. Quinolone derivatives containing strained spirocycle as orally active glycogen synthase kinase 3beta (GSK-3beta) inhibitors for type 2 diabetics. Bioorg. Med. Chem 2012, 20(3):1188-1200.
47. Wang Y., Feng W., Xue W., Tan Y., Hein D.W., Li X.K., et al. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage, and remodeling. Diabetes 2009, 58(6):1391-1402.
48. Zhande R., Mitchell J., Wu J., Sun X. Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol. Cell. Biol 2002, 22(4):1016-1026.
49. Zisman A., Peroni O.D., Abel E.D., Michael M.D., Mauvais-Jarvis F., Lowell B.B., et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med 2000, 6(8):924-928.